Daxor (DXR) vs Lucid Diagnostics (LUCD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Daxor (DXR) has outperformed Lucid Diagnostics (LUCD) over the past year, losing 43.5% versus a loss of 64.7%. Over five years, DXR leads with a -32.3% price change compared with -95.6% for LUCD. Lucid Diagnostics is the larger company by market cap ($72.6 million vs $43.5 million), about 1.7 times the size.
Daxor converts more of its revenue into profit, with a net margin of -496.8% versus -1232.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXR | LUCD |
|---|---|---|
| Share price | $7.45 | $0.3727 |
| Market cap | $43.49M | $72.57M |
| 1-day change | -7.33% | -3.52% |
| YTD return | -49.49% | -65.81% |
| 1-year return | -43.52% | -64.67% |
| 5-year return | -32.27% | -95.58% |
| P/E ratio (TTM) | 6.77 | — |
| EPS (TTM) | $1.10 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.45M | $4.71M |
| Revenue growth (YoY) | -8.42% | +8.28% |
| Net income (latest FY) | $-7.19M | $-58.01M |
| Gross margin | 54.89% | -41.73% |
| Operating margin | -400.07% | -1054.82% |
| Net margin | -496.81% | -1232.68% |
| 52-week high | $14.76 | $1.63 |
| 52-week low | $6.94 | $0.303 |
| Distance from 52-week high | -49.53% | -77.12% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +168.46% | +973.25% |
| Average volume | 22.43K | 5.15M |
| Shares outstanding | 5.84M | 194.71M |
| Employees | — | 82 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DXR has outperformed LUCD by 21.2 percentage points over the past year.
- Daxor is more profitable, keeping -496.8 cents of every revenue dollar as net income versus -1232.7 cents for Lucid Diagnostics.
- Lucid Diagnostics grew revenue faster in its latest fiscal year (+8.28% vs -8.42%).
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Health Care · Medical/Dental Instruments
About Lucid Diagnostics
LUCD stock →Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
Health Care · Medical/Dental Instruments · 82 employees
DXR vs LUCD FAQ
Which is bigger, Daxor or Lucid Diagnostics?
Lucid Diagnostics (LUCD) is larger, with a market capitalization of $72.57M compared with $43.49M for Daxor (DXR).
Which stock has performed better over the past year, DXR or LUCD?
DXR returned -43.52% over the past 12 months, compared with -64.67% for LUCD (price return, excluding dividends). Past performance does not predict future results.
Are Daxor and Lucid Diagnostics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.